Therapeutic efficacy of antitumor dendritic cell vaccinations correlates with persistent Th1 responses, high intratumor CD8+ T cell recruitment and low relative regulatory T cell infiltration
/in Glioblastoma, International Publications /von 2008-03-28 / Cancer Immunol. Immunother. 2008 Dec;57(12):1745-56Hyperthermia improves the antitumour effect of metronomic cyclophosphamide in a rat transplantable brain tumour
/in Glioblastoma, International Publications /von 2008-03-04 / Radiother Oncol 2008 Mar;86(3):435-42Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy
/in Glioblastoma, International Publications /von 2008-02-01 / J Clin Neurosci 2008 Feb;15(2):114-21Dendritic cell-based immunotherapy for malignant glioma
/in Glioblastoma, International Publications /von 2008-02-01 / Neurosci Bull 2008 Feb;24(1):39-44Dendritic cell immunotherapy for malignant gliomas
/in Dendritic Cells, Glioblastoma, International Publications /von 2008-01-01 / Rev Recent Clin Trials 2008 Jan;3(1):10-21Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas
/in Glioblastoma, International Publications /von 2007-12-19 / J Transl Med 2007 Dec;5:67[Dendritic cells pulsed with glioma RNA induce immunity against intracranial gliomas]
/in Dendritic Cells, Glioblastoma, International Publications /von 2007-11-01 / Zhejiang Da Xue Xue Bao Yi Xue Ban 2007 Nov;36(6):592-7Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma
/in Glioblastoma, International Publications /von 2007-07-20 / Immunology 2007 Dec;122(4):615-22Use of interferon-alpha-induced dendritic cells in the therapy of patients with malignant brain gliomas
/in Glioblastoma, International Publications /von 2007-04-01 / Bull. Exp. Biol. Med. 2007 Apr;143(4):528-34
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution